Ryan Jacobs, MD, Levine Cancer Institute, Charlotte, NC, discusses 5-year follow-up results from the CAPTIVATE study, which explored long-term outcomes after undetectable MRD with fixed-duration ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia (CLL).

These findings were presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans, LA, by first author John N. Allan, Weill Cornell Medicine, New York, NY.

Transcript:

My name is Dr. Ryan Jacobs. I'm a CLL specialist and the clinical director of the Lymphoma Division at Levine Cancer Institute in Charlotte, North Carolina.

I am going to talk today about the presentation that Dr. Allan gave on Saturday for the CAPTIVATE study, looking specifically at patients that had received ibrutinib plus venetoclax for a combination of 1 year, after a 3-month Ibrutinib lead-in—and how those patients did that had obtained minimal residual disease (MRD) negativity at the end of that 1 year of combination in both the blood and the marrow.

We now have 5-year follow up after these patients were randomly assigned to either receive placebo or ibrutinib. It's a great thing for our CLL patients, I feel. At this point, there is no statistically significant difference between those patients that continued on to placebo vs ibrutinib.

I think this is an important study [because] we hope that eventually we will have FDA approval to have this combination as a possibility. It has a 5-year efficacy of 88% in the placebo group of [progression-free survival] PFS. It represents a really great option for CLL patients who are interested in an oral-only, time-defined therapy that would ultimately limit toxicities, and in particular, limit financial toxicity.
 

Source:

Allan JN, Siddiqi T, Kipps TJ, et al. Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study. Presented at the  ASH Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, and virtual. Abstract 92.